A Shanghai biotech just got the green light for the first-ever randomized CAR-T trial in liver cancer. The early data: a 50% response rate in patients who had run out of options. If it works, it could crack open the solid tumor door that CAR-T has been banging on for a decade.
The Wall That CAR-T Couldn't Climb
CAR-T cell therapy has been a miracle worker in blood cancers. Leukemia, lymphoma, myeloma: it's racked up seven FDA approvals and counting. But solid tumors? That's been a graveyard of failed ambitions.
The problem is almost comically unfair. Blood cancers float around in easy-to-reach places, wearing a nice uniform target on their surface (like CD19). Solid tumors hide behind walls of hostile tissue, suppress the immune cells that show up, and constantly change their surface markers to dodge attacks. Think of it as the difference between catching fish in a barrel and hunting a chameleon in a jungle, while the jungle is actively trying to kill you.
No CAR-T product has ever been approved for a solid tumor. Anywhere in the world. Until now, most attempts produced little more than fleeting responses and a lot of disappointment across roughly 405 clinical trials.
That's why what just happened in China matters.
A First for Liver Cancer
Shanghai-based OriCell Therapeutics announced on June 8, 2026 that China's drug regulator, the NMPA, cleared its CAR-T therapy Ori-C101 to enter a confirmatory Phase II trial in advanced liver cancer. Specifically, in patients with hepatocellular carcinoma (HCC) who've already failed at least two rounds of treatment.
This is the first time any CAR-T product targeting liver cancer has reached a randomized, registration-intent Phase II study. It's also the first GPC3-directed immune cell therapy globally to hit this milestone. "Registration-intent" means the trial is designed to support an actual drug approval, not just generate data for a poster at a conference.
The trial will be prospective, randomized, open-label, and run across multiple centers in China. It's co-led by Professor Fan Jia, an academician at the Chinese Academy of Sciences, and Professor Qin Shukui from Nanjing Tianyinshan Hospital.
Why GPC3 Is the Key to the Door
Ori-C101 works by targeting a protein called glypican-3 (GPC3), and understanding GPC3 is critical to understanding why this approach has a real shot.
Get tomorrow's biotech intelligence before your competitors.
Join thousands of biotech professionals who start their day with our free, daily briefing.
GPC3 is what scientists call an "oncofetal antigen." It's active during embryonic development, then goes quiet in adults. But in liver cancer, it wakes back up. About 70 to 80 percent of HCC tumors express GPC3 on their surface, making it an unusually common target in a solid tumor.
The real beauty, though, is specificity. GPC3 is virtually absent in normal adult liver tissue, healthy organs, and benign liver conditions like cirrhosis or fatty liver disease. That's a rare and valuable trait. Many solid tumor targets (HER2, EGFR, mesothelin) also show up on normal tissues, creating dangerous "on-target, off-tumor" side effects. GPC3 largely avoids that problem.
It's also not just a passive marker sitting on the cell surface. GPC3 actively fuels tumor growth through Wnt signaling, a pathway that drives cancer cell proliferation. Higher GPC3 expression correlates with worse prognosis. So you're not just tagging the cancer; you're targeting something that makes it more aggressive.
The Data That Got OriCell Here
The NMPA's decision wasn't a leap of faith. It was backed by results from OriCell's Phase Ib BEACON study, presented at ASCO 2026.
Among 18 patients who could be evaluated for efficacy, the overall response rate hit 50%. That's remarkable for a group of patients who had already burned through at least two lines of therapy, including both targeted drugs (TKIs) and immunotherapy (checkpoint inhibitors). These weren't early-stage patients with lots of options left.
At the recommended dose for the Phase II trial, results were even more striking: a 66.7% response rate with a disease control rate near 90%. Almost nine out of ten responders showed tumor shrinkage by their very first scan after infusion.
Durability looked promising too. One patient achieved a complete response by month four and was still in remission at 24 months. Across the study, median overall survival reached 21.4 months, with 12-month survival at 69.3%.
On the safety side, things looked manageable. No cases of ICANS (a type of brain toxicity that can plague CAR-T therapies). No off-tumor toxicity. Cytokine release syndrome (CRS), the inflammatory storm that accompanies most CAR-T treatments, stayed within controllable grades. Earlier Phase I data did flag two grade 4 CRS events at higher doses, but both resolved within a week with standard treatment.
The Enormous Unmet Need
Liver cancer is the third leading cause of cancer death worldwide, and China carries a staggering share of the burden: roughly half of all global HCC cases. Most are driven by chronic hepatitis B infection, and because screening is often inadequate, patients frequently show up with advanced disease that can't be surgically removed.
First-line treatment has improved. Combinations of checkpoint inhibitors with anti-VEGF drugs (like atezolizumab plus bevacizumab) have become the functional standard for fit patients. Second-line options exist, mostly TKIs like regorafenib. But by the time patients reach a third line of therapy? There's essentially no established standard of care. Doctors cycle through remaining agents based on educated guesses and whatever the patient's liver can still tolerate.
The attrition is brutal. Many patients never make it to a third line because their underlying cirrhosis catches up to them first. Those who do tend to have good performance status but very few evidence-backed options.
That's exactly the population Ori-C101 is targeting.
OriCell: Small Company, Big Ambitions
OriCell isn't a household name, even by biotech standards. Founded in 2015 as an offshoot of Origincell Technology Group and renamed in 2021, it's a clinical-stage company with a focus on CAR-T for both blood cancers and solid tumors.
The company has steadily attracted serious capital. A $120 million Series B in 2022 was followed by a $70 million Series C1 in January 2026, backed by a mix that includes Qiming Venture Partners, a sovereign wealth fund, and several institutional investors. Its pipeline extends beyond liver cancer: OriCAR-017, a CAR-T for relapsed/refractory multiple myeloma, earned an oral presentation at ASCO 2022.
But Ori-C101 is the crown jewel. If the confirmatory Phase II succeeds, it could become the first CAR-T therapy approved for a solid tumor indication in China, and potentially the world.
What to Watch For
Solid tumor CAR-T has been the industry's white whale for over a decade. The challenges (hostile tumor microenvironment, antigen escape, poor T-cell infiltration) haven't disappeared. A randomized Phase II in 18-plus patients with earlier phase data is encouraging, but it's not a guarantee.
The key questions: Can Ori-C101 beat whatever standard comparator arm the trial uses? Will the responses hold up in a larger, more diverse group? And can OriCell manufacture and deliver a personalized, autologous cell therapy at scale across multiple Chinese centers?
If the answers are yes, this isn't just a win for OriCell. It's a proof of concept that CAR-T can work in solid tumors, period. And that would change the entire conversation about what cell therapy can do.
Clinical & Regulatory4 min read
This Tiny Danish Biotech Is Betting Against the Hottest Drug Strategy in Medicine
Everyone building obesity drugs wants to activate the GIP receptor. Antag Therapeutics just showed up at ADA 2026 with human data proving the opposite approach is safe. Their contrarian bet could reshape how we treat the patients that current blockbusters leave behind.
